Previous close | 249.40 |
Open | 250.39 |
Bid | 250.85 x 900 |
Ask | 252.30 x 800 |
Day's range | 249.98 - 252.92 |
52-week range | 182.09 - 259.00 |
Volume | |
Avg. volume | 2,665,966 |
Market cap | 186.013B |
Beta (5Y monthly) | 0.86 |
PE ratio (TTM) | 44.43 |
EPS (TTM) | 5.66 |
Earnings date | 23 Apr 2024 - 29 Apr 2024 |
Forward dividend & yield | 1.08 (0.43%) |
Ex-dividend date | 27 Mar 2024 |
1y target est | 260.70 |
The latest trading day saw Danaher (DHR) settling at $251.47, representing a +0.83% change from its previous close.
Danaher (DHR) gains from strength in academic and life science research markets, Abcam buyout and pro-investor policies. However, softness in its Biotechnology and Diagnostics units is concerning.
Danaher (DHR) reachead $253.10 at the closing of the latest trading day, reflecting a +0.12% change compared to its last close.